Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer

被引:38
作者
Monk, Bradley J. [1 ,2 ]
Pandite, Lini N. [3 ]
机构
[1] Creighton Univ, Sch Med, St Josephs Hosp, Phoenix, AZ USA
[2] Med Ctr, Phoenix, AZ USA
[3] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
关键词
D O I
10.1200/JCO.2011.38.8777
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:4845 / 4845
页数:1
相关论文
共 1 条
[1]   Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer [J].
Monk, Bradley J. ;
Lopez, Luis Mas ;
Zarba, Juan J. ;
Oaknin, Ana ;
Tarpin, Carole ;
Termrungruanglert, Wichai ;
Alber, Jacquelyn A. ;
Ding, Jie ;
Stutts, Melissa W. ;
Pandite, Lini N. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3562-3569